Multifactorial Acute Renal Failure Treated with Percutaneous Targeted Renal Therapy (TRT): A Case of “Dialysis Rescue”

Targeted renal therapy (TRT) with direct intrarenal artery fenoldopam (FEN) infusions were used to treat a multifactorial acute renal failure (ARF) patient with acute limb ischemia, contrast-induced nephropathy (CIN) and sepsis. TRT was initially infused periprocedurally for CIN prophylaxis. Congestive heart failure (CHF), sepsis and ARF developed 48 hours later, requiring dialysis. TRT was restarted during the third dialysis treatment with immediate return of renal function and urine outputs > 100 cc/hour, avoiding further dialysis. Catheter-delivered TRT has shown benefits in CIN prevention by increasing the glomerular filtration rate (GFR) by 25%.¹ We report a multifactorial ARF case in which TRT facilitated “rescue from dialysis”. Case Report. A 79 year-old diabetic male with several chronically infected diabetic foot ulcers was transferred emergently with a cold, pulseless left leg. The patient arrived fully anticoagulated with an 8 Fr right femoral sheath. During a percutaneous interventional revascularization attempt at the referring facility, the superficial femoral, popliteal and all infrapopliteal arteries developed thrombosis, with resultant acute limb ischemia. N-acetylcysteine, FEN and bicarbonate hydration were not used before transfer, and 240 cc of iso-osmolar contrast was utilized immediately prior to transfer. The patient’s past history included ischemic cardiomyopathy with an ejection fraction of 20% and multiple episodes of CHF. Just 6 months prior to transfer, the patient required 8 weeks of dialysis for ARF precipitated by pneumonitis, CHF, sepsis and CIN during left renal stenting. Pertinent laboratory findings on transfer included the following: Creatinine (Cr) of 2.8 mg/dL, BUN of 64 mg/dL, Cr clearance (CrCl) of 19 mL/minute, hematocrit of 25.2% and glucose of 258 mg/dL. All other serum lab values were normal including potassium, pH, CPK and bicarbonate. The patient was afebrile, with a heart rate of 72 and blood pressure of 110/70 mmHg. Physical exam was unremarkable except for the noted cold ischemic left leg with several infected foot ulcers. The patient’s urine output was Discussion. TTRT refers to direct bilateral intrarenal artery therapeutic infusions of fluids that may be potentially applicable to a wide range of clinical conditions including CIN prophylaxis and sepsis. Theoretically, TRT therapy may have benefit in CHF with cardiorenal syndrome and in worsening renal insufficiency during cardiac and vascular surgical procedures.^1–2 The Benephit PV Infusion system is FDA-approved and clinically available and consists of a 5 Fr single-port and 8 Fr dual-port system. The system includes an introducer sheath and infusion catheter with bifurcated low-profile arms that are easily directed into both renal arteries (Figure 2). FEN is a short-acting selective dopamine-1 receptor agonist and vasodilator that is the only agent known to increase renal cortical and medullary blood flow.³ Intravenous FEN has a serum T 1/2 of 5 minutes and can cause systemic hypotension at low doses of 0.05–0.¹ mcq/kg/minute, as demonstrated in the CONTRAST trial.⁴ It can be theorized that the poor CONTRAST trial results comparing intravenous FEN with hydration in CIN prevention were due to an inability to deliver therapeutic FEN doses directly to the renal nephrons. Direct high-dose intrarenal artery infusion of FEN in concept has the potential to deliver selective renal vasodilatation with increased cortical and medullary blood flow, thereby increasing the GFR.^1,3 Tierstein et al recently reported the safety and feasibility of TRT utilizing FEN 0.4 mcq/kg/minute in 33 percutaneous coronary intervention patients at high risk for CIN.¹ Inulin was used to measure GFR and FEN levels were measured. Several key TRT hypotheses were proven. No patient developed CIN, systemic FEN levels were lower with intravenous FEN versus TRT, and GFR was significantly increased with TRT versus intravenous FEN (23.6% versus 4.9%; p 1 The GFR remaind elevated by 25% for 2 hours after discontinuing TRT versus a 14% decrease in GFR in patients receiving placebo.¹ Further ongoing clinical trials are attempting to validate TRT in percutaneous coronary interventions, cardiothoracic and vascular surgery and peripheral endovascular interventions. Recent data have demonstrated GFR to be a strong predictor of outcomes in patients after acute myocardial infarction, CHF and in overall cardiovascular events in several large population studies.^5–11 Khan et al analyzed the GFR in 6,640 CHF patients and reported the rate of decline in GFR as a strong predictor of increased mortality independent of worsening CHF and baseline kidney function.⁶ Most recently, a decreased GFR of 12–14 Hills et al analyzed 2,067 CABG patients from the United Kingdom and found 37% had a preoperative GFR 13 Cooper et al reviewed 483,914 CABG patients using the Society of Thoracic Surgeons national database and found preoperative renal insufficiency (RI) to be common, with 51% having mild RI (GFR 60–90 mL/minute), 24% moderate RI (GFR 30–59 mL/minute), and 2% severe RI ( 90 mL/minute) to 9.3% (GFR 12 Interestingly, the proposed pathogenesis of ARF associated with CIN and sepsis are similar with the final common pathway leading to intense renal medullary vasoconstriction with the resulting sequelae of a vicious cycle of worsening ischemia, decreased renal medullary blood flow, cellular hypoxia, acidosis, endothelial dysfunction, hypercoagulability, glomerular microvascular thrombosis and acute tubular necrosis.^2,3,18,19 CIN is not uncommon and is now the third leading cause of hospital-acquired ARF.^15,16 The long-term survival of cardiovascular patients who develop ARF and require permanent dialysis is poor, with a 2-year survival rate of 5,12,15 In the United States each year, sepsis results in 210,000 deaths, which exceeds the reported deaths due to myocardial infarction.²⁰ ARF occurs in 23–51% of the 700,000 patients yearly who develop sepsis, with a mortality rate of 45–70% resulting in > 200,000 deaths.^18–20 ARF has been shown to occur in 51% of sepsis patients with positive blood cultures.^18–20 The mortality rate from sepsis with ARF is 70% versus 45% with ARF alone, therefore identifying this combination of ARF and sepsis as a major U.S. healthcare issue.^2,20 Morelli et al reported a prospective, double-blind, placebo-controlled, prophylactic, intravenous, low-dose (0.09 mcq/kg/minute) FEN trial in 300 patients with sepsis.² This study demonstrated safety and that the incidence of protocol-defined ARF and length of ICU stay, as well as the increase of serum Cr, were significantly lower in the FEN group. However, the probability of death and the difference in the incidence of severe ARF and dialysis demonstrated only a favorable trend and did not reach statistical significance in this small trial.² In early sepsis, vasoconstriction with intact tubular function predominates, therefore, it could be theorized that early TTRT with high-dose FEN could potentially be an effective early treatment strategy.² This early interventional TTRT strategy appears reasonable when considering there are no proven early or late therapeutic strategies to prevent dialysis for patients who develop ARF due to CIN, sepsis, or a combination of both, as likely occurred in this patient. In conclusion, worsening renal function, as estimated or calculated by GFR, is associated with poor outcomes in a wide range of cardiovascular and noncardiovascular patients including sepsis. This single case report does not definitively prove TRT with FEN “rescued” this patient from multifactorial ARF, and it is likely that the early renal recovery was secondary to multiple therapies including TRT. It is, however, intriguing to now have the availability of percutaneous catheter-directed renal artery access for therapeutic infusions capable of significantly increasing the GFR. TRT very likely was clinically important to this patient’s recovery when considering the pathogenesis of ARF in CIN and sepsis, and the increase in GFR associated with TRT. The lack of any effective percutaneous or nonpercutaneous medical interventional therapy in the very large number of patients with rapidly worsening renal function destined for dialysis have lowered our threshold to utilize TTRT in a wide range of clinical scenarios including CIN prevention, coronary and peripheral vascular interventions, CABG, EVAR, CHF and “renal rescue” in sepsis. Pilot and randomized trials are being organized in each of these clinical scenarios, and it is highly likely that other therapeutic infusions besides FEN could also potentially improve clinical outcomes.

1. Teirstein P, Price MJ, Mathur V, et al. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol 2006;97:1076–1081. 2. Morelli A, Ricci Z, Pietropaoli P, et al. Prophylactic fenoldopam for renal protection in sepsis: A randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005;33:2451–2456. 3. Stone GO, Roxana M. Pharmacologic prevention of contrast-induced nephropathy. J Invasive Cardiol 2005;17(Suppl C):9C–14C. 4. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003;290:2284–2291. 5. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischaemic Research group. Ann Intern Med 1998;128:194–203. 6. Khan NA, Ma I, Levin A, et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006;17:244–253. 7 . Gottleib SS, Abraham W, Butler J, et al. The prognostic importance of difference definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136–141. 8. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Eng J Med 1998;339:799–805. 9 . McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004–1009. 10 . McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679–684. 11. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high risk combination. Ann Intern Med 2002;137:563–570. 12. Cooper WA, O’Brien SM, Peterson ED, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery. Circulation 2006;113:1063–1070. 13. Hillis GS, Croal BL, Cuthbertson BH, et al. Renal function and outcome from coronary artery bypass grafting: Impact on mortality after a 2.3 year follow-up. Circulation 2006;113:1056–1062. 14. Azizzadeh A, Sanchez LA, Sicard GA, et al. Glomerular filtration rate is a predictor of mortality after endovascular abdominal aortic aneurysm repair. J Vasc Surg 2005;43:14–18. 15. McCullough Pa, Woln R, Rocher LL, et al. acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368–375. 16. Mehran R, Aymong ED, Nikolsky E, et al. A simple score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393–1399. 17. Edelstein CL, Schrier RW. Pathophysiology of ischemic acute renal failure. In: Schrier RW (ed.). Diseases of the Kidney and Urinary Tract (7th ed. Vol. 2). Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 1041–1069. 18. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351:159–169. 19. Riedmann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003;112:460–470. 20. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.